These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34149812)

  • 21. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
    Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
    Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Santoro AL; Drummond RD; Silva IT; Ferreira SS; Juliano L; Vendramini PH; Lemos MBDC; Eberlin MN; Andrade VP
    Cancer Res; 2020 Mar; 80(6):1246-1257. PubMed ID: 31911556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?
    Kothari C; Clemenceau A; Ouellette G; Ennour-Idrissi K; Michaud A; Diorio C; Durocher F
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.
    Rane SU; Mirza H; Grigoriadis A; Pinder SE
    Breast Cancer Res Treat; 2015 Aug; 153(1):101-21. PubMed ID: 26255059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
    Murphy DS; Hoare SF; Going JJ; Mallon EE; George WD; Kaye SB; Brown R; Black DM; Keith WN
    J Natl Cancer Inst; 1995 Nov; 87(22):1694-704. PubMed ID: 7473818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
    Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
    Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the natural history of ductal carcinoma in situ based on population data.
    Chootipongchaivat S; van Ravesteyn NT; Li X; Huang H; Weedon-Fekjær H; Ryser MD; Weaver DL; Burnside ES; Heckman-Stoddard BM; de Koning HJ; Lee SJ
    Breast Cancer Res; 2020 May; 22(1):53. PubMed ID: 32460821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
    Guvakova MA; Prabakaran I; Wu Z; Hoffman DI; Huang Y; Tchou J; Zhang PJ
    Breast Cancer Res Treat; 2020 Sep; 183(2):333-346. PubMed ID: 32683564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.
    Klimov S; Miligy IM; Gertych A; Jiang Y; Toss MS; Rida P; Ellis IO; Green A; Krishnamurti U; Rakha EA; Aneja R
    Breast Cancer Res; 2019 Jul; 21(1):83. PubMed ID: 31358020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 33. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
    Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.
    Carraro DM; Elias EV; Andrade VP
    Biosci Rep; 2014 Feb; 34(1):. PubMed ID: 27919043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
    Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
    Mardekian SK; Bombonati A; Palazzo JP
    Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics.
    Tsang WY; Chan JK
    Am J Surg Pathol; 1996 Aug; 20(8):921-43. PubMed ID: 8712293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?
    Shi B; Grimm LJ; Mazurowski MA; Baker JA; Marks JR; King LM; Maley CC; Hwang ES; Lo JY
    Acad Radiol; 2017 Sep; 24(9):1139-1147. PubMed ID: 28506510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.